|
Groups
|
Dose (mg/kg)
|
Growth of weight (g)
|
Organ indices (mg/g)
|
|---|
|
Spleen
|
Thymus
|
Heart
|
Liver
|
Lung
|
Kidney
|
|---|
|
S180 tumor model
|
|
Control
|
-
|
4.08 ± 0.61
|
7.02 ± 0.70
|
2.24 ± 0.22
|
5.17 ± 0.40
|
63.71 ± 3.53
|
6.88 ± 0.52
|
13.01 ± 0.61
|
|
TAFU
|
20
|
2.36 ± 0.81###
|
6.86 ± 0.20##
|
2.43 ± 0.35##
|
4.34 ± 0.12
|
63.28 ± 2.10#
|
7.29 ± 0.37
|
13.00 ± 0.50
|
| |
40
|
2.84 ± 0.74#
|
6.67 ± 0.17##
|
1.98 ± 0.12*, #
|
4.67 ± 0.20
|
56.04 ± 1.11*
|
6.62 ± 0.21
|
12.29 ± 0.37
|
| |
80
|
2.45 ± 0.50##
|
5.43 ± 0.11*, #
|
1.84 ± 0.17*
|
4.55 ± 0.30
|
58.50 ± 0.82
|
6.39 ± 0.45
|
12.88 ± 0.63
|
|
CTX
|
20
|
−1.82 ± 0.64***
|
4.26 ± 0.16***
|
1.30 ± 0.15**
|
4.73 ± 0.18
|
52.72 ± 3.30*
|
6.75 ± 0.39
|
12.81 ± 0.59
|
|
LLC tumor model
|
|
Control
|
-
|
0.64 ± 0.48
|
6.07 ± 0.91
|
1.57 ± 0.32
|
5.93 ± 0.48
|
57.54 ± 3.99
|
6.90 ± 0.52
|
13.63 ± 0.60
|
|
TAFU
|
20
|
0.58 ± 0.68###
|
7.74 ± 0.57##
|
1.25 ± 0.13###
|
5.22 ± 0.32#
|
58.69 ± 1.32#
|
7.20 ± 0.33*
|
12.54 ± 0.55
|
| |
40
|
0.37 ± 0.32*, ##
|
7.53 ± 0.38##
|
1.18 ± 0.04##
|
5.25 ± 0.43#
|
53.44 ± 1.20#
|
7.33 ± 0.10
|
11.17 ± 0.22
|
| |
80
|
0.29 ± 0.50*, ##
|
5.68 ± 0.82#
|
1.09 ± 0.07*, ##
|
4.86 ± 0.12*
|
53.85 ± 4.96#
|
6.87 ± 0.60#
|
11.69 ± 0.40
|
|
CTX
|
20
|
−1.88 ± 0.71***
|
4.05 ± 0.42**
|
0.41 ± 0.05***
|
4.38 ± 0.17*
|
44.34 ± 3.59*
|
6.80 ± 0.54
|
11.96 ± 0.62
|
- The reported values are the means ± S.E.M. (n = 10). Significant differences compared with Control group were designated as *P < 0.05, **P < 0.01 and ***P < 0.001; and those compared with CTX group as #P < 0.05, ##P < 0.01 and ###P < 0.001.
